Safety and Efficacy Phase I/IIa Trial of an RNActive-Derived Cancer Vaccine in Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC).
Phase of Trial: Phase I/II
Latest Information Update: 20 Nov 2017
At a glance
- Drugs CV 9201 (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- Sponsors CureVac
- 18 Sep 2014 Results published in a Boehringer Ingelheim and CureVac media release.
- 24 Oct 2012 Planned number of patients changed from 33 to 46 as reported by EudraCT record.
- 18 Sep 2012 Status changed from active, no longer recruiting to completed, according to a CureVac media release.